NYTimes: Pfizer’s Early Data Shows Vaccine Is More Than 90% Effective

Pfizer, a pharmaceutical company based in New York, have collaborated with the German drugmaker BioNTech to announce that an early analysis of clinical trials has suggested the robust effectiveness of their new vaccine. Pfizer plans to gain approval for emergency authorization of the vaccine later this month by the FDA. There can be about 15 to 20 million people with the immunization doses by the end of the year. Eleven vaccines, four of them based in the U.S.,  continue to perform in late-stage trials. For the full article, click here. For more articles about Covid-19, click here.